<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289496</url>
  </required_header>
  <id_info>
    <org_study_id>ML25553</org_study_id>
    <secondary_id>Control Number: 143155</secondary_id>
    <nct_id>NCT01289496</nct_id>
  </id_info>
  <brief_title>Ribavirin Dose Optimization for the Treatment of Hepatitis C</brief_title>
  <official_title>Ribavirin Dose Optimization for the Treatment of Hepatitis C: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients for whom treatment with peginterferon plus ribavirin was unsuccessful represent a
      category of patients for whom there is currently no worthwhile therapeutic alternative.

      Several studies have shown that there is a relation between plasma ribavirin concentrations
      and treatment response. Adequate ribavirin plasma concentrations, especially during the first
      12 weeks of treatment, should be associated with a better chance of response to the
      treatment.

      The strategy for this study will be to use a loading dose of ribavirin before beginning the
      treatment with peg-interferon, thereby allowing for optimal ribavirin concentrations to be
      reached, and possibly improving the effectiveness of the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) analysis assay</measure>
    <time_frame>up to 24 weeks post treatment</time_frame>
    <description>Qualitative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Kinetics</measure>
    <time_frame>up to 24 weeks post treatment</time_frame>
    <description>Plasma Ribavirin (RBV) Assays; Immune Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils</measure>
    <time_frame>up to 24-48 weeks of treatment</time_frame>
    <description>If neutrophils are &lt; 500/mm, neupogen may be added</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>up to 24-48 weeks of treatment</time_frame>
    <description>If hemoglobin is &lt; 100g/L, erythropoietin and/or transfusions may be prescribed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Peg-interferon alpha-2a, Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).
This is a pilot study with no control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-interferon alpha-2a, Ribavirin</intervention_name>
    <description>4 weeks RBV priming;
24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);
24 weeks Follow-Up
Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.
Ribavirin 200 mg tablets</description>
    <arm_group_label>Peg-interferon alpha-2a, Ribavirin</arm_group_label>
    <other_name>Peg-interféron alpha-2a (PEGASYS)</other_name>
    <other_name>Ribavirin (COPEGUS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin
             (non-response: HCV-RNA decreased less than 2 logs after 3 months of treatment;
             relapse: HCV-RNA that becomes positive again after treatment is stopped

          -  Compensated hepatic disease (Child-Pugh ≤ 6)

          -  Provision by patient of his or her written consent

        Exclusion Criteria:

          -  Females who are pregnant or lactating will be excluded

          -  Renal failure (estimated glomerular filtration rate &lt; 50 ml/min)

          -  A contraindication to treatment with peginterferon plus ribavirin (uncontrolled
             psychiatric illness, pregnancy/nursing/non-use of effective contraceptive method,
             uncontrolled epilepsy for at least 6 months, heart failure, unstable angina,
             hemoglobin &lt; 120 g/L, neutrophils &lt; 1,000/mm3, platelets &lt; 50 x 109/L, or any other
             condition that, in the investigator's opinion, contraindicates use of the treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Villeneuve, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol. 2003 Apr;55(4):360-7.</citation>
    <PMID>12680884</PMID>
  </reference>
  <reference>
    <citation>Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol. 2006 Dec;62(6):710-4.</citation>
    <PMID>17118126</PMID>
  </reference>
  <reference>
    <citation>Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther. 2008;13(4):607-11.</citation>
    <PMID>18672540</PMID>
  </reference>
  <reference>
    <citation>Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci. 2007 Mar;52(3):732-6.</citation>
    <PMID>17253142</PMID>
  </reference>
  <reference>
    <citation>Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999;19 Suppl 1:17-24. Review.</citation>
    <PMID>10349689</PMID>
  </reference>
  <reference>
    <citation>Uchida M, Hamada A, Yamasaki M, Fujiyama S, Sasaki Y, Saito H. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet. 2004 Dec;19(6):438-43.</citation>
    <PMID>15681898</PMID>
  </reference>
  <reference>
    <citation>Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology. 2005;48(2-3):138-44.</citation>
    <PMID>15812187</PMID>
  </reference>
  <reference>
    <citation>Badr G, Bédard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve JP, Haddad EK, Sékaly RP, Bruneau J, Shoukry NH. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol. 2008 Oct;82(20):10017-31. doi: 10.1128/JVI.01083-08. Epub 2008 Jul 30.</citation>
    <PMID>18667516</PMID>
  </reference>
  <reference>
    <citation>Hofer H, Donnerer J, Sator K, Staufer K, Scherzer TM, Dejaco C, Sator M, Kessler H, Ferenci P. Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy. J Hepatol. 2010 Jun;52(6):812-6. doi: 10.1016/j.jhep.2009.12.039. Epub 2010 Mar 23.</citation>
    <PMID>20399525</PMID>
  </reference>
  <reference>
    <citation>Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000 Oct;22(5):555-65.</citation>
    <PMID>11034261</PMID>
  </reference>
  <reference>
    <citation>Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2002 Oct;72(4):349-61.</citation>
    <PMID>12386637</PMID>
  </reference>
  <reference>
    <citation>Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009 Apr 21;150(8):528-40.</citation>
    <PMID>19380853</PMID>
  </reference>
  <reference>
    <citation>Kauppila A, Cantell K, Jänne O, Kokko E, Vihko R. Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. Int J Cancer. 1982 Mar 15;29(3):291-4.</citation>
    <PMID>6175589</PMID>
  </reference>
  <reference>
    <citation>Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, Denis F, Lunel F, Calès P, Lefebvre A, Fauchais AL, Liozon E, Vidal E. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008 May;47(5):1453-61. doi: 10.1002/hep.22217.</citation>
    <PMID>18435468</PMID>
  </reference>
  <reference>
    <citation>Maeda Y, Kiribayashi Y, Moriya T, Maruhashi A, Omoda K, Funakoshi S, Murakami T, Takano M. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit. 2004 Feb;26(1):9-15.</citation>
    <PMID>14749543</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ribavirin</keyword>
  <keyword>Pegasys</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

